Nicholas James Hornstein, MD, PhD

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

The most common toxicity associated with TAS-102 was neutropenia, with grade 3 events occurring in 73.3% of patients with colorectal cancer.

“…I like TAS-102 as an agent, but we need better drugs than we have right now to clear ctDNA and cure patients,” said Hornstein, MD, PhD.

The phase 2 INTERCEPT-TT trial showed that TAS-102 induced ctDNA clearance following adjuvant chemotherapy in patients with colorectal cancer.

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

The CHALLENGE trial in CRC studied structured exercise and demonstrated a DFS benefit comparable to or exceeding oxaliplatin chemotherapy.